Scribe Therapeutics Inc. Common Stock (NASDAQ:SCTX) — Market Cap & Net Worth
Market Cap & Net Worth: Scribe Therapeutics Inc. Common Stock (SCTX)
Scribe Therapeutics Inc. Common Stock (NASDAQ:SCTX) has a market capitalization of $379.31 Million ($379.31 Million) as of August 24, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #13788 globally and #3319 in its home market, demonstrating a 67.55% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Scribe Therapeutics Inc. Common Stock's stock price $34.13 by its total outstanding shares 16182010 (16.18 Million). Check current stock price of Scribe Therapeutics Inc. Common Stock for real-time trading data and today's change.
Scribe Therapeutics Inc. Common Stock Market Cap History: 2026 to 2026
Scribe Therapeutics Inc. Common Stock's market capitalization history from 2026 to 2026. Data shows growth from $552.29 Million to $552.29 Million (0.00% CAGR).
Scribe Therapeutics Inc. Common Stock Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Scribe Therapeutics Inc. Common Stock's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check Scribe Therapeutics Inc. Common Stock (SCTX) net assets to evaluate the company's book value and shareholders' equity.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of SCTX by Market Capitalization
Companies near Scribe Therapeutics Inc. Common Stock in the global market cap rankings as of August 24, 2026. Also see cash efficiency ratio of Scribe Therapeutics Inc. Common Stock for how efficiently the company converts equity into cash flow.
Key companies related to Scribe Therapeutics Inc. Common Stock by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #188 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #323 globally with a market cap of $83.19 Billion USD.
- CSL Ltd (AU:CSL): Ranked #475 globally with a market cap of $57.77 Billion USD ( AU$81.65 Billion AUD).
- Samsung Biologics Co Ltd (KO:207940): Ranked #564 globally with a market cap of $48.66 Billion USD ( ₩71.80 Trillion KRW).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #188 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $548.05 |
| #323 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $83.19 Billion | $834.04 |
| #475 | CSL Ltd | AU:CSL | $57.77 Billion | AU$168.30 |
| #564 | Samsung Biologics Co Ltd | KO:207940 | $48.66 Billion | ₩1551000.00 |
Scribe Therapeutics Inc. Common Stock Historical Marketcap From 2026 to 2026
Between 2026 and today, Scribe Therapeutics Inc. Common Stock's market cap moved from $552.29 Million to $ 552.29 Million, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $552.29 Million | -- |
End of Day Market Cap According to Different Sources
On Aug 24th, 2026 the market cap of Scribe Therapeutics Inc. Common Stock was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $379.31 Million USD |
| MoneyControl | $379.31 Million USD |
| MarketWatch | $379.31 Million USD |
| marketcap.company | $379.31 Million USD |
| Reuters | $379.31 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Scribe Therapeutics Inc. Common Stock
Scribe Therapeutics Inc. operates as a clinical-stage biotechnology company, focuses on research and developing genetic medicines using CRISPR-based tools to address the root cause of diseases, with a primary focus on cardiometabolic conditions in the United States. The company offers STX-1150 designed to be a single-course in vivo epigenetic silencing treatment targeting the PCSK9 gene; STX-1200… Read more